Published • loading... • Updated
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Summary by ADKhabar
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
May 11, 2026 04:00 ET | Source: ENA Respiratory MELBOURNE, Australia, May 11, 2026 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the successful completion of Part A of its Phase IIa community study of INNA-051, and progression […] The post ENA Respiratory Successfully Completes First Part …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
